Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
301-320 of 1,782 trials

Acetic Acid for Healing Skin Ulcers

We are studying whether acetic acid can help improve the healing of skin ulcers with biofilm compared to standard treatment. This trial will look at healing rates and safety over several weeks.

Skin Ulcer>2 yearsEfficacy phase (II)Standard MedicinesDermatology

Pulmonary Arterial Hypertension: Triple Therapy Study

We are investigating whether a new combination of treatments, including an injectable medication, improves health outcomes for patients with pulmonary arterial hypertension. This study compares it to a standard oral treatment to see which is more effective.

Pulmonary Arterial Hypertension6-12 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Non-ST Elevation Acute Coronary Syndrome: Aspirin Omission Study

We are investigating if avoiding aspirin can reduce bleeding risks for patients with non-ST segment elevation acute coronary syndrome. The goal is to see if this approach is as effective as current treatments for heart issues.

Non-ST-Segment Elevation Acute Coronary Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Cervical Cancer: Volrustomig Treatment Study

We are studying whether volrustomig is safe and effective for women and young adults with high-risk locally advanced cervical cancer after initial treatment. This trial compares volrustomig to a placebo to see if it improves health outcomes.

Locally Advanced Cervical CancerConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesPartially RemoteOncology

Chronic Hepatitis D: Bulevirtide Treatment Study

We are studying the effects of Bulevirtide in patients with chronic hepatitis D to see how well it reduces the virus and improves liver health. This research will help us understand the treatment's safety and effectiveness over time.

Hepatitis DConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesHepatologyInfectious Diseases

Secukinumab: Long-Term Safety Study

We are evaluating the long-term safety of Secukinumab for patients who have previously participated in a related study. This trial will help us understand any potential side effects of continued treatment.

Psoriatic ArthritisAnkylosing SpondylitisNon-radiographic Axial Spondyloarthritis>2 yearsMonitoring phase (IV)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyInternal MedicineRheumatology

Atopic Dermatitis: Methotrexate Injection Study

We are testing whether subcutaneous methotrexate can improve skin symptoms in adults with moderate to severe atopic dermatitis compared to a placebo. The study also examines safety and quality of life for participants.

Moderate to Severe Atopic Dermatitis3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesAllergologyDermatology

Metastatic Breast Cancer: Somatostatin Receptor PET Scan Study

We are studying how somatostatin receptors behave in metastatic breast cancer using DOTATOC-68Ga PET scans. This may help us understand the disease better and improve future imaging techniques.

Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Fibrotic Lung Disease: Inhaled Treprostinil Study

We are evaluating the long-term safety of inhaled treprostinil for individuals with fibrotic lung diseases. This study is for those who have previously participated in related trials and need ongoing treatment.

Lung Fibrosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicinePulmonology

Head and Neck Cancer: Pembrolizumab with Radiotherapy

We are studying if adding radiotherapy to pembrolizumab helps patients with limited spread of head and neck cancer live longer and feel better. This trial focuses on those with a specific type of cancer and aims to compare treatment effects and safety.

Squamous Cell Carcinoma of the Head and Neck>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Cardiac Surgery: DOAC vs. Vitamin K Antagonist Study

We are studying the safety of two blood thinners for patients with atrial fibrillation after heart surgery. This research may help determine the best anticoagulation treatment for these patients.

Atrial Fibrillation>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Aortic Stenosis: Protamine for Heart Procedure Safety

We are studying whether using protamine sulfate can reduce complications like strokes and bleeding during heart valve surgery. This trial is for patients with aortic stenosis undergoing transcatheter aortic valve implantation.

Cardiovascular Disorder>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Acquired Hemophagocytic Syndrome: Ruxolitinib Study

We are studying whether ruxolitinib, combined with standard care, can improve organ function and survival in critically ill patients with acquired hemophagocytic syndrome. This trial also looks at the safety and effects of the drug on various health markers.

Haemophagocytic Syndrome1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInternal Medicine

aHUS: Switching to Iptacopan Treatment

We are studying whether switching from anti-C5 antibody therapy to iptacopan can help people with aHUS avoid complications. The trial will also assess the safety and effects on blood and kidney health.

Atypical Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyNephrology

Large Incisional Hernia: Botulinum Toxin A Injection Study

We are investigating whether injecting botulinum toxin A before surgery helps reduce complications and improve recovery for patients with large incisional hernias. This study compares the effects of BTA to a placebo injection.

Incisional Hernia>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementGastroenterologyOrthopedics and Traumatology

Trigeminal Neuralgia: Botox Treatment Study

We are exploring whether Botox can effectively reduce pain in patients with trigeminal neuralgia compared to a placebo. Additionally, we’re investigating if specific biomarkers can help predict treatment response.

Trigeminal Neuralgia3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesNeurology

Hypotension Treatment: Early Vasopressor Therapy

We are studying whether starting vasopressor therapy early helps hypotensive patients in the emergency department recover faster than standard fluid therapy. This may reduce the need for intensive care admission.

Low Blood Pressure (Hypotension)Shock>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInfectious DiseasesInternal MedicinePulmonology

Advanced Non-Small Cell Lung Cancer: THIO with Cemiplimab

We are studying the safety and effectiveness of a new treatment combining THIO and cemiplimab for people with advanced non-small cell lung cancer. This trial aims to find out if this combination works better than THIO alone for patients who have already been treated.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Chronic Lymphocytic Leukemia: Venetoclax and Obinutuzumab Study

We are assessing the effectiveness and safety of a combination treatment for adults with recurring chronic lymphocytic leukemia. This study aims to understand how well the treatment works and what side effects may occur.

Recurrent Chronic Lymphocytic Leukemia1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Alzheimer's Disease: Rotigotine and Rivastigmine Study

We are testing a combination of rotigotine and rivastigmine to see if it improves thinking skills and daily activities in people with mild to moderate Alzheimer's disease. This study compares the new treatment to rivastigmine with a placebo.

Mild to Moderate Alzheimer's Disease3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteNeurology